γ-secretase inhibitor (GSI) treatment inhibited the binding of NOTCH3/MAML1 complex to HES1 promoter (Figure 1C), indicating that Notch pathway is active in these breast cancer cells and MAML1 might be a co-activator of Notch signaling in breast cancer. This evidence concerns the gene NOTCH3 and breast carcinoma.